This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kramer, J. L. Articles by Greene, M. H. Search for Related Content PubMed PubMed Citation Articles by Kramer, J. L. Articles by Greene, M. H. Social Bookmarking                            What's this?

Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers

From the Clinical Genetics and Biostatistics Branches, Division of Cancer Epidemiology and Genetics, and Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD

Address reprint requests to Joan L. Kramer, MD, Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Room 7016, MSC 7231, Rockville, MD 20852; e-mail: kramerj{at}mail.nih.gov

PURPOSE: Breast cancer penetrance estimates in BRCA1 mutation carriers have varied from 40% to 85%; this heterogeneity has been attributed to variations in risk among different study populations. No study has taken oophorectomy status into account in estimating penetrance. Because prophylactic oophorectomy reduces breast cancer risk by approximately 50%, we hypothesized that population differences in oophorectomy prevalence might significantly influence breast cancer penetrance estimates.

METHODS: Females from multiple-case breast/ovarian cancer families that segregate deleterious BRCA1 mutations were observed prospectively for breast cancer incidence and oophorectomy.

RESULTS: Within this cohort, 33 cases of breast cancer developed in 98 women with deleterious BRCA1 mutations during follow-up, yielding an estimated cumulative lifetime breast cancer risk of 80%. This estimate increased to 94% when the study participants were censored at the time of oophorectomy. Six of the 33 mutation-positive women who underwent oophorectomy during follow-up developed breast cancer, compared with 27 of 65 mutation carriers with intact ovaries (hazard ratio = 0.38; 95% CI, 0.15 to 0.97). Estimates of absolute breast cancer risk demonstrated that the protective effect of oophorectomy was strongest among women who were premenopausal at the time of surgery. When surgical status was ignored, the strong protective effect of oophorectomy, coupled with the high prevalence of the procedure in these families, led to a significantly lower estimate of the breast cancer penetrance in BRCA1 mutation carriers.

CONCLUSION: Differing rates of oophorectomy likely represent an underappreciated basis for a portion of the heterogeneity in estimated breast cancer penetrance described in BRCA mutation carriers, particularly mutation carriers from extensively affected, multiple-case families.

Supported by the Intramural Research Program of the National Cancer Institute, Rockville, MD.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. T. Loud, A. C.M. Thiebaut, A. D. Abati, A. C. Filie, K. Nichols, D. Danforth, R. Giusti, S. A. Prindiville, and M. H. Greene Ductal Lavage in Women from BRCA1/2 Families: Is There a Future for Ductal Lavage in Women at Increased Genetic Risk of Breast Cancer? Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1243 - 1251. [Abstract] [Full Text] [PDF]

				T. R. Rebbeck, N. D. Kauff, and S. M. Domchek Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers J Natl Cancer Inst, January 21, 2009; 101(2): 80 - 87. [Abstract] [Full Text] [PDF]

				M. H. Greene and P. L. Mai What Have We Learned from Risk-Reducing Salpingo-oophorectomy? J Natl Cancer Inst, January 21, 2009; 101(2): 70 - 71. [Full Text] [PDF]

				N. D. Kauff, S. M. Domchek, T. M. Friebel, M. E. Robson, J. Lee, J. E. Garber, C. Isaacs, D. G. Evans, H. Lynch, R. A. Eeles, et al. Risk-Reducing Salpingo-Oophorectomy for the Prevention of BRCA1- and BRCA2-Associated Breast and Gynecologic Cancer: A Multicenter, Prospective Study J. Clin. Oncol., March 10, 2008; 26(8): 1331 - 1337. [Abstract] [Full Text] [PDF]

				M. Fatouros, G. Baltoyiannis, and D. H. Roukos The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations Ann. Surg. Oncol., January 1, 2008; 15(1): 21 - 33. [Abstract] [Full Text] [PDF]

				J. Chang-Claude, N. Andrieu, M. Rookus, R. Brohet, A. C. Antoniou, S. Peock, R. Davidson, L. Izatt, T. Cole, C. Nogues, et al. Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 740 - 746. [Abstract] [Full Text] [PDF]

				J. B. Madalinska, M. van Beurden, E. M.A. Bleiker, H. B. Valdimarsdottir, L. Lubsen-Brandsma, L. F. Massuger, M. J.E. Mourits, K. N. Gaarenstroom, E. B.L. van Dorst, H. van der Putten, et al. Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers J. Clin. Oncol., January 20, 2007; 25(3): 301 - 307. [Abstract] [Full Text] [PDF]

				J. B. Madalinska, M. van Beurden, E. M.A. Bleiker, H. B. Valdimarsdottir, J. Hollenstein, L. F. Massuger, K. N. Gaarenstroom, M. J.E. Mourits, R. H.M. Verheijen, E. B.L. van Dorst, et al. The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy J. Clin. Oncol., August 1, 2006; 24(22): 3576 - 3582. [Abstract] [Full Text] [PDF]

				T. Walsh, S. Casadei, K. H. Coats, E. Swisher, S. M. Stray, J. Higgins, K. C. Roach, J. Mandell, M. K. Lee, S. Ciernikova, et al. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast Cancer JAMA, March 22, 2006; 295(12): 1379 - 1388. [Abstract] [Full Text] [PDF]

				S. Chen, E. S. Iversen, T. Friebel, D. Finkelstein, B. L. Weber, A. Eisen, L. E. Peterson, J. M. Schildkraut, C. Isaacs, B. N. Peshkin, et al. Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample J. Clin. Oncol., February 20, 2006; 24(6): 863 - 871. [Abstract] [Full Text] [PDF]